This article examines the practical considerations, technique, and evidence surrounding thigh versus stomach injections for Wegovy, providing guidance to help patients optimise their treatment experience
NICE recommends Wegovy for adults who: Have a body mass index (BMI) of 35 kg/m or more (or 30 kg/m or more for people from some minority ethnic groups), or Have a BMI of 3034.9 kg/m (or 27.529.9 kg/m for people from some minority ethnic groups) with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease) Are participating in a specialist weight management service that provides dietary advice, physical activity support, and behavioural interventions Treatment should be discontinued after a maximum of 2 years within the specialist weight management service
In the U.K., between 2007 and October 2025, 1,296 yellow card reports of pancreatitis linked to GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists were reported, of which 19 were fatal
List cellular mechanisms: inflammation modulation, fibroblast ECM output, oxidative stress reduction, and glycation changes
Is Blood in the Stool Serious
.png.jpg)
